Nasdaq
$0.4059▼ 1.41%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $77.4MShares out 1.900M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 2d agoAfter-hours26.10.23 05:348-KKey event#●●●#●●●#●●●
Lucid Diagnostics Inc.Bullish
Lucid Diagnostics Inc. completed a $15 million offering of Series C Convertible Preferred Stock on October 21, 2026. As a result, the conversion price of the company's existing senior secured convertible notes was reduced to $0.3519, and the company entered into a registration rights agreement for the common stock issuable upon conversion of the new preferred shares.…more
$0.4059-1.41%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16After-hours26.10.17 05:308-KKey event
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. received a notice from Nasdaq stating that its common stock failed to meet the minimum $1 bid price requirement under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days. The company has been granted a 180-day compliance period, ending April 12, 2027, to regain compliance by maintaining a closing bid price of at least $1 for ten consecutive business days.…more
$0.4059-1.41%vs prev closeView filingShare - 9.22Pre-market26.09.22 22:068-KKey event
Lucid Diagnostics Inc.
Lucid Diagnostics has achieved significant progress in payment, billing, and coding pathways for its EsoGuard and EsoCheck products. A Medicare advisory panel recommended maintaining the existing payment basis for EsoGuard, while the AMA approved a new CPT code for EsoCheck and the CDC favorably reviewed a proposal for a new ICD-10-CM diagnosis code for positive results.…more
$0.4059-1.41%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoAfter-hours26.10.23 05:28Bullish#●●●#●●●#●●●
Lucid Diagnostics Secures Medicare Payments and $15M Private Placement
Lucid Diagnostics has begun receiving Medicare payments for its EsoGuard test and closed a $15 million private placement of Series C convertible preferred stock. The proceeds are intended to accelerate commercial operations, though the conversion terms introduce potential equity dilution.…more
$0.4059-1.41%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga